Skip to main content
Top

Impact of a new diagnostic pathway for prostate cancer—from systematic transrectal to targeted MRI fusion transperineal biopsies

Abstract

Purpose

Advancements in prostate cancer diagnostics have changed the diagnostic pathway from traditional ultrasound-guided systematic transrectal biopsies to pre-biopsy prostate multiparametric MRI and targeted transperineal biopsies. This study aims to determine changes in prostate cancer detection rates, clinical outcomes, and treatment before (2018) and after (2023) implementing the new diagnostic pathway.

Methods

This retrospective study comprises two cohorts from two Danish hospitals—one from 2018 (n = 266) and one from 2023 (n = 304). In each cohort, men with suspected prostate cancer who underwent biopsies were analysed. Data were obtained from medical records. Categorical variables were compared using Chi-square or Fisher’s exact test. Continuous variables were analysed with the Mann–Whitney U test in STATA version 18. P value ≤ 0.05 was considered significant.

Results

The 2023 cohort showed a significantly higher detection of clinically significant prostate cancer (Gleason ≥ 3 + 4) compared to the 2018 cohort (65.41% vs. 41%, p < 0.01). Median Gleason scores increased from 6 to 7 (IQR 6–7 vs. 6–8, p < 0.01). Hospital admissions decreased from 11.3% to 3% (p < 0.01) in the 2023 cohort. Treatment and D’Amico’s risk groups showed no significant changes. Limitations include potential selection bias from only including biopsied patients and findings limited to two Danish hospitals, reducing generalizability.

Conclusion

Transitioning to targeted transperineal biopsies improved cancer detection and reduced complications. While the Gleason score increased, risk groups and treatment plans remained unchanged. These results support implementation in clinical practice, though further studies are needed to assess long-term outcomes and broader applicability.
Title
Impact of a new diagnostic pathway for prostate cancer—from systematic transrectal to targeted MRI fusion transperineal biopsies
Authors
Sara Vejlgaard Kristensen
Martin Wirenfeldt
Katrine Thelle
Else Brohm Kallestrup
Mads Hvid Poulsen
Publication date
03-11-2025
Publisher
Springer Netherlands
Published in
International Urology and Nephrology
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-025-04875-7
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on progress in colorectal cancer

  • Live
  • Webinar | 11-12-2025 | 18:00 (CET)

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Watch it live: Thursday 11 December 2025, 18:00-19:30 (CET)

Prof. Antoni Castells
Prof. Edward Giovannucci
Developed by: Springer Medicine
Join the webinar
Webinar

2025 ESMO Congress hub

Unlock your free and exclusive access to expert interviews, news, and more from the annual congress of the European Society for Medical Oncology.

Read more

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Developed by: Springer Medicine
Watch now
Video
Image Credits
Colon cancer illustration/© (M) KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images, Cancer cell screening and treatment concept/© artacet / iStock / Getty Images Plus, Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images